v3.26.3
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
cvr
position
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
position
segment
cvr
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jan. 31, 2010
cvr
Property, Plant, and Equipment              
Gain (loss) in estimated fair value of contingent liabilities     $ (5,775,000) $ (1,475,000)      
Number of operating segments | segment     1        
Number of reportable segments | segment     1        
Number of positions in an unrealized loss position | position 125   125        
Unrealized losses $ 1,700,000   $ 1,700,000        
Credit losses related to available-for-sale debt securities 0 $ 0 0 0      
Increase (decrease) in allowance for credit losses 300,000 300,000 300,000 400,000      
Inventory write-down 0 0 0 0      
Inventory 14,508,000   14,508,000   $ 9,126,000    
Fair value adjustments to partner program derivatives 0 833,000 0 0      
Equity method investments 48,445,000   48,445,000   46,500,000    
Unrealized gain (loss) on equity method investments     (1,575,000) 7,000      
Unrecognized tax benefits $ 17,285,000   $ 17,285,000   $ 16,588,000    
Metabasis Therapeutics              
Property, Plant, and Equipment              
Number of contingent value rights issued | cvr             4
Number of contingent value rights outstanding | cvr 2   2        
Performance Shares              
Property, Plant, and Equipment              
Performance period for awards (in years) 3 years            
Performance Shares | Minimum              
Property, Plant, and Equipment              
Payout range (as a percent) 0.00%            
Performance Shares | Maximum              
Property, Plant, and Equipment              
Payout range (as a percent) 200.00%            
RemainCo              
Property, Plant, and Equipment              
Investment owned, net assets, percentage 25.00%   25.00%        
Equity securities in Primrose Bio              
Property, Plant, and Equipment              
Investment owned, net assets, percentage 27.30%   27.30%   31.50%    
Impairment of equity method investment $ 0 0 $ 0 0      
Equity method investments           $ 0  
AvenCell              
Property, Plant, and Equipment              
Investment owned, net assets, percentage 10.70%   10.70%        
Equity method investments $ 3,200,000   $ 3,200,000        
Pelthos Series A convertible preferred shares              
Property, Plant, and Equipment              
Unrealized gain (loss) on equity method investments (24,900,000) 52,800,000 (34,200,000) 52,800,000      
Agenus Warrant And Castle Creek Warrant              
Property, Plant, and Equipment              
Fair value adjustments to partner program derivatives   $ (700,000)   $ (100,000)      
Warrants And Option              
Property, Plant, and Equipment              
Fair value adjustments to partner program derivatives 8,500,000   9,100,000        
Captisol              
Property, Plant, and Equipment              
Inventory $ 1,600,000   $ 1,600,000   $ 2,100,000    
Equity securities in Primrose Bio              
Property, Plant, and Equipment              
Percentage of milestones (as a percent) 50.00%   50.00%